Engineered nano-based device for glioblastoma multiforme therapy - Nano4Glio
Nano4Glio aims to develop an innovative implantable device for the continuous and targeted treatment of glioblastoma multiforme. This biodegradable device is designed to co-deliver the gold-standard drug (temozolomide) and a MGMT protein inhibitor directly to brain tumor cells, overcoming the limitations of current GBM therapies, such as low drug bioavailability and resistance mechanisms. By enhancing drug delivery across the blood-brain barrier and enabling localized, sustained release, Nano4Glio seeks to improve therapeutic outcomes and reduce side effects for GBM patients.In its early stages, Nano4Glio has demonstrated promising in vitro results, successfully validating the efficacy of its drug-loaded nanoparticles in glioblastoma cell models. These tests showed significant uptake by tumor cells, reinforcing the potential of the NPs to enhance drug delivery and therapeutic effectiveness. Additionally, substantial progress has been made in the development of a biodegradable hydrogel capable of incorporating and releasing drug-loaded nanoparticles effectively. This innovative hydrogel design is optimized for sustained drug release, with the potential to offer a single administration treatment that could last up to six weeks. Since the project began, the Nano4Glio team has published four articles in high-quality journals (all Q1) related to the project's scope, reinforcing the scientific relevance and innovation of the project in the field of glioblastoma treatment. The Nano4Glio team is actively preparing for a future patent submission to protect the unique composition and design of the nanoparticle-hydrogel delivery system. This will allow for future intellectual property protection and potential commercialization of the device. To further ensure the project's relevance and feasibility, a multi-disciplinary advisory board has been established, comprising experts from clinical, social and industrial fields. Their expertise and insights bring a comprehensive perspective to the project, supporting Nano4Glio's alignment with regulatory standards and clinical needs. This collaborative, multi-stakeholder effort enhances the project's potential for future clinical translation by incorporating valuable input from various sectors of the glioblastoma treatment community.
